A typical five-day treatment course would include six vials, which would equate to $2,340 per patient, Daniel O'Day, Gilead Sciences chairman and CEO, said in the letter. The US government will continue to manage US allocations of remdesivir to hospitals through September, the company said. Now, as we transition beyond the donation period and set a price for remdesivir, the same principle applies," O'Day said in the letter. About the drug: Remdesivir, which is currently administered intravenously through infusions, is the only drug that has an emergency use authorization from the US Food and Drug Administration to treat coronavirus infections. "President Trump has secured half a million courses of treatment of remdesivir through September," Azar told ABC's George Stephanopoulos.

Source: CNN June 29, 2020 12:45 UTC